Highlights AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Real-time Estimate Cboe BZX Other stock markets 10:55:42 2024-07-08 EDT			5-day change	1st Jan Change
167.2 ^USD	+1.47%		-1.40%	+8.39%

02:45pm	That's not so bad, is it?
07-05	Sector Update: Health Care Stocks Steady Premarket Friday	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

That's not so bad, is it?	08:45am
Sector Update: Health Care Stocks Steady Premarket Friday	07-05	MT
AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	07-05	MT
AbbVie cuts 2024 profit forecast	07-03	RE
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	06-27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	06-27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
AbbVie: acquisition of Celsius for $250 million	06-27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	06-27	DJ
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	06-27	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	06-27	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	06-26	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-26	CI
AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.	06-26	CI
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	06-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Highlights

Filters